Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Measuring daily activity in patients with ALS and healthy controls

Official title: Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects

Run by Centre Hospitalier Universitaire de Liege · NCT04882904 · Data updated 2026-11-12

This study is testing how active people with ALS are compared to healthy individuals by using a special device to track their daily movements over a year.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment45 (estimated)
SponsorCentre Hospitalier Universitaire de Liege
Academic / other
Locations1 site (Liège, Liège)
StatusRecruiting
StartedSeptember 25, 2020
Main results expectedSeptember 2026
Study endsDecember 2026
Registry record updatedDecember 5, 2025
Trial IDNCT04882904 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults over 18 years old with a clinically defined or probable diagnosis of ALS.

Probably not a fit

Patients with significant cognitive disorders or other pathologies affecting motor function may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to continuously measure the activity levels of patients diagnosed with amyotrophic lateral sclerosis (ALS) and compare them with healthy control subjects. Approximately 20 ALS patients will be enrolled voluntarily and assessed every three months over a year. Participants will undergo various clinical examinations and tests, including the 6-minute walk test and electromyography, and will wear a device called Actimyo daily for one month to monitor their activity levels. The study seeks to gather comprehensive data on the daily living activities of ALS patients to better understand the disease's impact.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the daily activity patterns of ALS patients, potentially leading to improved management strategies.

How similar studies have gone: While similar studies have explored activity measurement in ALS, this specific approach using continuous monitoring with Actimyo is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
* Over 18 years old.
* Signed informed consent
* If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.

Exclusion Criteria:

* Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
* Any other previous or present pathology having an impact on motor function.
* Recent surgery or trauma (less than 6 months) in the upper or lower limbs.
* Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.
* Patients participating in an interventional clinical trial.

Where it's running

  • CHR Citadelle
    Liège, Liège, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Implanted Brain-Computer Interface to Help People with Severe Arm Impairment

    We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.

    Recruiting Neuralink Corp · Miami, Florida · NCT07929792

  • Brain-computer interface chat tool for people with ALS

    This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.

    Recruiting Cognixion · Santa Barbara, California · NCT07871071

  • BIIB147 safety and how it behaves in adults with ALS

    This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.

    Recruiting at 2 sites Phase 1/2 Biogen · St Louis, Missouri and 1 other locations · NCT07855211

  • Aims to restore UNC13A function in people with ALS

    This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.

    Recruiting at 6 sites Phase 1/2 Trace Neuroscience, Inc. · Lübeck, Schleswig-Holstein and 5 other locations · NCT07674667

  • LTX-002 in adults with ALS

    A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.

    Recruiting at 4 sites Phase 1/2 Leal Therapeutics, Inc · Lübeck and 4 other locations · NCT07660614

  • Repeated ultrasound-assisted blood-brain barrier opening in ALS

    This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.

    Recruiting Phase 1/2 Assistance Publique - Hôpitaux de Paris · Paris · NCT07571486

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.